180 related articles for article (PubMed ID: 11001550)
1. Recombinant vaccinia virus encoding human MUC1 and IL2 as immunotherapy in patients with breast cancer.
Scholl SM; Balloul JM; Le Goc G; Bizouarne N; Schatz C; Kieny MP; von Mensdorff-Pouilly S; Vincent-Salomon A; Deneux L; Tartour E; Fridman W; Pouillart P; Acres B
J Immunother; 2000; 23(5):570-80. PubMed ID: 11001550
[TBL] [Abstract][Full Text] [Related]
2. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
3. [Vaccination against the tumoral mammary epithelial cells expressing MUC1 mucin].
Scholl SM; Pouillart P
Bull Cancer; 1997 Jan; 84(1):61-4. PubMed ID: 9180861
[TBL] [Abstract][Full Text] [Related]
4. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2.
Trevor KT; Hersh EM; Brailey J; Balloul JM; Acres B
Cancer Immunol Immunother; 2001 Oct; 50(8):397-407. PubMed ID: 11726134
[TBL] [Abstract][Full Text] [Related]
5. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
6. Technology evaluation: TG-1031, Transgene SA.
Doehn C; Jocham D
Curr Opin Mol Ther; 2000 Feb; 2(1):106-11. PubMed ID: 11249647
[TBL] [Abstract][Full Text] [Related]
7. An anti-MUC1-antibody-interleukin-2 fusion protein that activates resting NK cells to lysis of MUC1-positive tumour cells.
Heuser C; Ganser M; Hombach A; Brand H; Denton G; Hanisch FG; Abken H
Br J Cancer; 2003 Sep; 89(6):1130-9. PubMed ID: 12966437
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of antigen-specific gene therapy using a recombinant vaccinia virus encoding MUC-1 and IL-2 in MUC-1-positive patients with advanced prostate cancer.
Pantuck AJ; van Ophoven A; Gitlitz BJ; Tso CL; Acres B; Squiban P; Ross ME; Belldegrun AS; Figlin RA
J Immunother; 2004; 27(3):240-53. PubMed ID: 15076142
[TBL] [Abstract][Full Text] [Related]
9. Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2.
He J; Shen D; O'Donnell MA; Chang HR
Int J Oncol; 2002 Jun; 20(6):1305-11. PubMed ID: 12012014
[TBL] [Abstract][Full Text] [Related]
10. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
11. Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patients.
Snijdewint FG; von Mensdorff-Pouilly S; Karuntu-Wanamarta AH; Verstraeten AA; Livingston PO; Hilgers J; Kenemans P
Int J Cancer; 2001 Jul; 93(1):97-106. PubMed ID: 11391628
[TBL] [Abstract][Full Text] [Related]
12. Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
Karanikas V; Thynne G; Mitchell P; Ong CS; Gunawardana D; Blum R; Pearson J; Lodding J; Pietersz G; Broadbent R; Tait B; McKenzie IF
J Immunother; 2001; 24(2):172-83. PubMed ID: 11265775
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
14. Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E; Hu XF; Xing PX
Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
[TBL] [Abstract][Full Text] [Related]
15. Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin.
von Mensdorff-Pouilly S; Verstraeten AA; Kenemans P; Snijdewint FG; Kok A; Van Kamp GJ; Paul MA; Van Diest PJ; Meijer S; Hilgers J
J Clin Oncol; 2000 Feb; 18(3):574-83. PubMed ID: 10653872
[TBL] [Abstract][Full Text] [Related]
16. Reevaluation of the cellular immune response in breast cancer patients vaccinated with MUC1.
Musselli C; Ragupathi G; Gilewski T; Panageas KS; Spinat Y; Livingston PO
Int J Cancer; 2002 Feb; 97(5):660-7. PubMed ID: 11807794
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of a MUC1 vaccine composed of different doses of MUC1 peptide with SB-AS2 adjuvant in resected and locally advanced pancreatic cancer.
Ramanathan RK; Lee KM; McKolanis J; Hitbold E; Schraut W; Moser AJ; Warnick E; Whiteside T; Osborne J; Kim H; Day R; Troetschel M; Finn OJ
Cancer Immunol Immunother; 2005 Mar; 54(3):254-64. PubMed ID: 15372205
[TBL] [Abstract][Full Text] [Related]
18. Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine.
Chung MA; Luo Y; O'Donnell M; Rodriguez C; Heber W; Sharma S; Chang HR
Cancer Res; 2003 Mar; 63(6):1280-7. PubMed ID: 12649188
[TBL] [Abstract][Full Text] [Related]
19. The effect of T1 and T2 cytokines on the cytotoxic T cell response to mannan-MUC1.
Lees CJ; Apostolopoulos V; Acres B; Ong CS; Popovski V; McKenzie IF
Cancer Immunol Immunother; 2000 Feb; 48(11):644-52. PubMed ID: 10663612
[TBL] [Abstract][Full Text] [Related]
20. Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model.
Remy-Ziller C; Thioudellet C; Hortelano J; Gantzer M; Nourtier V; Claudepierre MC; Sansas B; Préville X; Bendjama K; Quemeneur E; Rittner K
Hum Vaccin Immunother; 2018 Jan; 14(1):140-145. PubMed ID: 28925793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
